BioSpace News Archive

American Lending Center (ALC), in partnership with its sister company Sunstone Management, have begun a series of donations to help mitigate the spread of the coronavirus. With the total number of confirmed cases above 28,000 and those in the US rising daily, the declared global health emergency requires a global response

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.

Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that it has filed a complaint in the U.S. District Court for the Southern District of New York asserting direct claims against Enzo and asserting both direct and derivative claims against members of its Board of Directors (the “Board”) (Case 1:20-cv-01021).

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced that it has received clearance from the U.S. Food & Drug Administration to market the Steerable PLATEAU Ti System.

Product launch and rapid development of the Logix Smart™ 2019-nCoV coronavirus test facilitated by Company’s proprietary technology platform

To increase the number of healthcare professionals in the Inland Empire and improve Member access to care, Inland Empire Health Plan is thrilled to announce its $40 million commitment over five years to launch the Healthcare Scholarship Fund.

eFFECTOR Therapeutics, Inc. announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 11 at 2:00 p.m. ET.

Natus Medical Incorporated announced financial results for the three months and full year ended December 31, 2019.

Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo

Myriad Genetics, Inc. announced financial results for its fiscal second-quarter 2020, provided an update on recent business highlights and provided revised fiscal year and third-quarter 2020 financial guidance.